TFRC and Patent ductus arteriosus: In addition, oncogenic RAS was reported to modulate mitochondrial metabolism, hence ROS generation, suppressing the respiratory chain complex I and III (Weinberg et al., 2010; Hu et al., 2012; Liou et al., 2016), regulating hypoxia-inducible factors (HIFs), HIF-1α and HIF-2α (Chun et al., 2010), or the transferrin receptor (TfR1) (Jeong et al., 2016) in CRC and PDA (Figure 2C).